Hello everyone, It's been interesting as I pursue recent posts about the future of Afrezza, the Mannkind/Sanofi agreement, and the stock price. In my attempts to buoy morale, let me offer the following observations/comments. First of all, we are still in the early stages of the Afrezza launch. While I understand everyone's panic and angst over the lack of stock momentum- please let me encourage everyone that in the history of stock launches - this launch is following a predictable course. the soft launch to Endos was well planned and calculated. This is not the first, nor will be the last product Sanofi has launched. They want success- but it will come over time. There is much they need to overcome, the poor rep of inhaled insulin (Exubera) not the least of obstacles. Secondly- this product will need Patient-driven marketing, as it will be positioned as an "upgrade" from current therapies, and there is little motivation for physicians to prescribe unless a patient asks for it. Look for a 3rd quarter DTC ad program. There will be patient support groups and educational efforts with CDEs to move interest in this disruptive therapy. Furthermore, let's not be concerned with an Afrezza 2.0. While intriguing as a concept - the costs of pursuing FDA approval of a hexametric insulin in the techno sphere device is cost-prohitivitive at this junction. And the script data is only indicative of a trend, due to the large volume of non- reporting pharmacies, so only use it to identify trends. I am a strong believer in what Afrezza can offer- please join me in being calm and patient.